Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Opioid receptors
- Alternative pre-mRNA splicing
- Evidence: multiple mu opioid receptors
- Alternative splicing of the mu opioid receptor gene, OPRM1
- The mouse OPRM1 gene: C-terminal full-length 7TM splice variants
- Truncated 6-TM splice variants
- Truncated 1-TM splice variants
- The three variants: summary
- Biased signaling at a single GPCR with different agonists
- Biased signaling at several splice variants of the same gene with a single agonist
- Morphine actions on mMOR-1, mMOR-1C & mMOR-1O
- Alternative splicing of the mu opioid receptor gene, OPRM1 (1)
- Differential expressions of mu receptor splice variant mRNAs in brain of four mouse strains
- Differential distribution of E4-associated variants (MOR-1) and E7-associated variants (MOR-1C)
- Alternative splicing of the mu opioid receptor gene, OPRM1 (2)
- Oprm1 Gene targeting mouse models
- Gene targeting strategy for C-terminal tails
- C-terminal truncation mouse models (1)
- Morphine tolerance and physical dependence in inbred mouse strains
- C-terminal truncation mouse models (2)
- Expression of variant mRNAs by RT-qPCR
- Saturation studies with [3H]DAMGO and [3H]naloxone
- MOR-derived endocytic recycling sequence (MRS)
- Morphine behavioral studies
- Radiant heat tail flick assay
- Morphine analgesia by cumulative dose-response curve
- Morphine tolerance
- Morphine dependence: naloxone-precipitated withdrawal
- Morphine reward: conditioned place preference (CPP)
- Effect of a vivo-morpholino antisense oligo on morphine tolerance and dependence in CD-1 mice
- Loss of morphine-induced desensitization of mu receptors in the hypothalamus and brainstem
- Comparison among the mutant mouse models
- Signaling bias
- A predicted phosphorylation code for high-affinity β-arrestin binding: PxPxxP/E/D or PxxPxxP/E/D
- Summary
- Acknowledgements
Topics Covered
- Extensive alternative pre-mRNA splicing of the mu opioid receptor gene (OPRM1)
- Distinct intracellular C-terminal tails in different full-length 7TM C-terminal variants
- Distinct in vivo functions of several C-terminal tails
- In vivo truncation of C-terminal tails encoded by E7 affects morphine tolerance and reward
- In vivo truncation of C-terminal tails encoded by E4 affects morphine tolerance and dependence
Links
Series:
Categories:
Talk Citation
Pan, Y. (2020, May 31). Biased signaling at mu opioid receptor splice variants [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/XIDD8431.Export Citation (RIS)
Publication History
Financial Disclosures
- Ying-Xian Pan is a co-scientific founder of Sparian Biosciences.
Other Talks in the Series: G Protein-Coupled Receptors (GPCRs) Signaling in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Ying-Xian Pan, I'm a member
of the Department of Neurology at
the Memorial Sloan-Kettering
Cancer Center.
My research interests have
long focused on GPCRs,
particularly the mu opioid receptors.
Today, I will talk about biased signaling
at the mu opioid receptor splice variants.
0:23
Earlier pharmacological studies defined
three types of opiate receptors,
mu, kappa and delta.
Molecular cloning led to
identification of their
corresponding genes OPRM1,
OPRK1, and OPRD1,
and their receptor proteins MOR-1 (MOP),
KOR-1 (KOP) and DOR-1 (DOP).
There is a fourth member of
the opioid receptor gene family,
OPRN1, encoding ORL-1 or NOP.
Structurally, NOP shares high
homology with the other three
opioid receptors, but
does not bind to any opiate.
The crystal structures of all
four receptors were resolved and
published in the same
issue of Nature in 2012.
The mu opioid receptor has a special
place in the opioid receptor family,
because it mediates the actions of
most of the clinically-used opioids
such as morphine, fentanyl and
methadone, as well as heroin.
Mu opioid agonists can
effectively relieve pain,
mainly severe pain such
as that caused by cancer.
However, they also cause many
side-effects including tolerance,
physical dependence, respiratory
depression, addiction and so on.
Our goal is to understand the molecular
mechanisms of opioid actions,
and we hope to develop better analgesic
drugs with limited side-effects.